Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 3;22(1):950.
doi: 10.1186/s12885-022-10026-3.

Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes

Yun Jiang  1   2 , Madilyn Mason  3 , Youmin Cho  3 , Ankita Chittiprolu  3 , Xingyu Zhang  4 , Karen Harden  3 , Yang Gong  5 , Marcelline R Harris  3 , Debra L Barton  3
Affiliations

Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes

Yun Jiang et al. BMC Cancer. .

Abstract

Background: More than 60% of cancer cases occur in older adults, and many are treated with oral anticancer agents. Yet, the treatment tolerability in older adults has not been fully understood due to their underrepresentation in oncology clinical trials, creating challenges for treatment decision-making and symptom management. The objective of this study was to investigate the tolerance of capecitabine, an example of oral chemotherapy, among older adults with cancer and explore factors associated with capecitabine-related side effects and treatment changes, to enhance supportive care.

Methods: A secondary analysis used combined data from electronic health records and a pilot study of patient-reported outcomes, with a total of 97 adult patients taking capecitabine during 2016-2017, including older adult patients aged 65 years or older (n = 43). The data extracted included patient socio-demographics, capecitabine information, side effects, and capecitabine treatment changes (dose reductions and dose interruptions). Bivariate correlations, negative binomial regression, and multiple linear regression were conducted for data analysis.

Results: Older adults were more likely to experience fatigue (86% vs. 51%, p = .001) and experienced more severe fatigue (β = 0.44, p = 0.03) and hand-foot syndrome (HFS) (β = 1.15, p = 0.004) than younger adults. The severity of fatigue and HFS were associated with the number of outpatient medications (β = 0.06, p = 0.006) and the duration of treatment (β = 0.50, p = 0.009), respectively. Correlations among side effects presented different patterns between younger and older adults. Although more older adults experienced dose reductions (21% vs. 13%) and dose interruptions (33% vs. 28%) than younger adults, the differences were not statistically different. Female sex, breast cancer diagnosis, capecitabine monotherapy, and severe HFS were found to be associated with dose reductions (p-values < 0.05).

Conclusions: Older adults were less likely to tolerate capecitabine treatment and had different co-occurring side effects compared to younger adults. While dose reductions are common among older adults, age 65 years or older may not be an independent factor of treatment changes. Other socio-demographic and clinical factors may be more likely to be associated. Future studies can be conducted to further explore older adults' tolerance to a variety of oral anticancer agents to generate more evidence to support optimal treatment decision-making and symptom management.

Keywords: Adverse effects; Capecitabine; Dose reduction; Older adults; Oral anticancer agents.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of competing interest with respect to the research, authorship, and/or publication of this article.

Figures

Fig. 1
Fig. 1
The severity of toxicities in older adults
Fig. 2
Fig. 2
Correlation among toxicities in older adults (a) and younger adults (b). Note: p-value < 0.05
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621. doi: 10.2147/PPA.S106629. - DOI - PMC - PubMed
    1. Cinar D, Tas D. Cancer in the elderly. North Clin Istanb. 2015;2(1):73–80. - PMC - PubMed
    1. Bhatt VR. Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities. Future Oncol. 2019;15(22):2557–2560. doi: 10.2217/fon-2019-0159. - DOI - PMC - PubMed
    1. Dunn C, Wilson A, Sitas F. Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer. Cancer Epidemiol. 2017;51:113–7. doi: 10.1016/j.canep.2017.11.002. - DOI - PubMed
    1. François E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, et al. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol. 2014;110(1):144–149. doi: 10.1016/j.radonc.2013.10.019. - DOI - PubMed

MeSH terms